We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aurinia Pharmaceuticals Inc | NASDAQ:AUPH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.02 | 0.39% | 5.19 | 3.08 | 5.99 | 5.545 | 5.09 | 5.34 | 1,696,503 | 05:00:07 |
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences.
Interested parties can also register and access these presentations under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com.
ABOUT AURINIA
Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005906/en/
Investor and Corporate: Dana Lynch, Corporate Communications & IR dlynch@auriniapharma.com
1 Year Aurinia Pharmaceuticals Chart |
1 Month Aurinia Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions